Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

665 ARTÍCULOS , VIENDO DEL 571 AL 585

Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis

d'Angremont E, Begemann MJH, van Laar T, Sommer IEC.

JAMA Neurol. 2023 Aug 1;80(8):813-823. doi: 10.1001/jamaneurol.2023.1835.

Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress

Yoo YM, Joo SS.

Int J Mol Sci. 2023 Jan 25;24(3):2381. doi: 10.3390/ijms24032381.

Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders

Nguyen TT, Nguyen-Thi PT, Nguyen THA, Ho TT, Tran NM, Van Vo T, Van Vo G.

Mol Diagn Ther. 2023 Jul;27(4):457-473. doi: 10.1007/s40291-023-00654-1. Epub 2023 May 22.

New insights into glycogen synthase kinase-3: A common target for neurodegenerative diseases

Wang C, Cui Y, Xu T, Zhou Y, Yang R, Wang T.

Biochem Pharmacol. 2023 Dec;218:115923. doi: 10.1016/j.bcp.2023.115923. Epub 2023 Nov 18.

Differential Role of Active Compounds in Mitophagy and Related Neurodegenerative Diseases

Makarov M, Korkotian E.

Toxins (Basel). 2023 Mar 6;15(3):202. doi: 10.3390/toxins15030202.

ER-phagy in neurodegeneration

Hill MA, Sykes AM, Mellick GD.

J Neurosci Res. 2023 Oct;101(10):1611-1623. doi: 10.1002/jnr.25225. Epub 2023 Jun 19.

The novel function of bexarotene for neurological diseases

Liu Y, Wang P, Jin G, Shi P, Zhao Y, Guo J, Yin Y, Shao Q, Li P, Yang P.

Ageing Res Rev. 2023 Sep;90:102021. doi: 10.1016/j.arr.2023.102021. Epub 2023 Jul 24.

The Neuropharmacological Evaluation of Seaweed: A Potential Therapeutic Source

Jannat K, Balakrishnan R, Han JH, Yu YJ, Kim GW, Choi DK.

Cells. 2023 Nov 18;12(22):2652. doi: 10.3390/cells12222652.

Impact of TRPV1 on Pathogenesis and Therapy of Neurodegenerative Diseases

Wang W, Sun T.

Molecules. 2023 Dec 28;29(1):181. doi: 10.3390/molecules29010181.

Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles-Focus on Alzheimer's and Parkinson's disease

Hernando S, Santos-Vizcaíno E, Igartua M, Hernandez RM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 Sep-Oct;15(5):e1898. doi: 10.1002/wnan.1898. Epub 2023 May 8.

Traversing through the cell signaling pathways of neuroprotection by betanin: therapeutic relevance to Alzheimer's Disease and Parkinson's Disease

Phukan BC, Roy R, Paul R, Mazumder MK, Nath J, Bhattacharya P, Borah A.

Metab Brain Dis. 2023 Mar;38(3):805-817. doi: 10.1007/s11011-023-01177-8. Epub 2023 Feb 6.

Pharmacological and Pathological Relevance of S100 Proteins in Neurological Disorders

Goswami D, Anuradha U, Angati A, Kumari N, Singh RK.

CNS Neurol Disord Drug Targets. 2023;22(10):1403-1416. doi: 10.2174/1871527322666221128160653.

Anti-amyloid potential of some phytochemicals against Aβ-peptide and α-synuclein, tau, prion, and Huntingtin protein

Jerom JP, Madhukumar S, Nair RH, Narayanan SP.

Drug Discov Today. 2023 Dec;28(12):103802. doi: 10.1016/j.drudis.2023.103802. Epub 2023 Oct 17.

LRRK2 and Parkinson's disease: from genetics to targeted therapy

Sosero YL, Gan-Or Z.

Ann Clin Transl Neurol. 2023 Jun;10(6):850-864. doi: 10.1002/acn3.51776. Epub 2023 Apr 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias